BGM Group Ltd. (NASDAQ:BGM) Short Interest Update

BGM Group Ltd. (NASDAQ:BGM) saw a significant increase in short interest in July. As of July 15th, there was short interest totaling 314,375 shares, an increase of 76.3% from the June 30th total of 178,275 shares. Based on an average daily trading volume, of 748,276 shares, the short-interest ratio is currently 0.4 days. Approximately 0.8% of the company’s shares are sold short.

BGM Group Stock Performance

Shares of BGM stock traded down $0.02 during mid-day trading on Thursday, reaching $0.27. 7,265 shares of the company’s stock traded hands, compared to its average volume of 303,612. The company’s 50-day moving average price is $0.33 and its 200-day moving average price is $0.91. BGM Group has a 12 month low of $0.25 and a 12 month high of $11.80.

BGM Group (NASDAQ:BGM) last issued its quarterly earnings results on Tuesday, July 21st. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $11.80 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of BGM Group in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On BGM Group

Several large investors have recently made changes to their positions in BGM. Geode Capital Management LLC purchased a new stake in shares of BGM Group in the 2nd quarter worth approximately $412,000. Mariner LLC purchased a new position in BGM Group during the third quarter valued at $267,000. Finally, Marshall Wace LLP bought a new stake in BGM Group in the second quarter worth $218,000.

About BGM Group

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.